![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Cirrhosis regression based on both Enhanced Liver Fibrosis (ELF) and Fibrotest after Direct-acting Hepatitis C therapeutics corresponds to a lower incidence rate of hepatocellular carcinoma below the cost-effective threshold for surveillance
|
|
|
EASL 2021 Presented at The International Liver Congress (EASL), 23-26 June 2021
Winston Dunn MD1, Devin Koestler2, Liyun Ni3, Kathryn Kersey3, Bruce Kreter3, Kyle Hammond3, Anand Chokkalingam3, Diana Brainard3, and Steven A Weinman MD PhD FAASLD1
(1)Internal Medicine, University of Kansas Medical Center, Kansas City, USA, (2)Biostatistics, University of Kansas Medical Center, Kansas City, USA,(3)Gilead Sciences, Inc. Foster City, USA
![0623211](../images/062321/062321-8/0623211.gif)
![0623212](../images/062321/062321-8/0623212.gif)
![0623213](../images/062321/062321-8/0623213.gif)
![0623214](../images/062321/062321-8/0623214.gif)
![0623215](../images/062321/062321-8/0623215.gif)
![0623216](../images/062321/062321-8/0623216.gif)
![0623217](../images/062321/062321-8/0623217.gif)
![0623218](../images/062321/062321-8/0623218.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|